Intepirdine, also known as SB-742457, also known as RVT-101, is a selective 5-HT6 receptor antagonist with potential cognition, memory, and learning-enhancing effects. It was under development by GlaxoSmithKline for the treatment of Alzheimer's disease and demonstrated some preliminary efficacy in phase II clinical trials. SB742457 can reverse age-related declines in delayed non-match-to-sample performance (DNMS). SB742457 shows increasing pro-cognitive effects in patients with AD.
臺州市科瑞生物技術有限公司
聯(lián)系商家時請?zhí)峒癱hemicalbook,有助于交易順利完成!
crene